Home » AstraZeneca and Bristol-Myers Squibb Resubmit Dapagliflozin New Drug Application for the Treatment of Type 2 Diabetes in the U.S
AstraZeneca and Bristol-Myers Squibb Resubmit Dapagliflozin New Drug Application for the Treatment of Type 2 Diabetes in the U.S
AstraZeneca and Bristol-Myers Squibb have resubmitted a New Drug Application for dapagliflozin for type 2 diabetes. The new submission includes new studies and more long-term data.
AstraZeneca
AstraZeneca
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May